- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
You are here
Rosette Lidereau, PhD
Department of Tumor Biology
Goal: To discover new preventive and treatment strategies for patients with metastatic breast cancer.
Impact: Dr. Lidereau has identified a protein called kindlin-1 that drives cancer cell invasion and metastasis. She and her team have designed novel inhibitors that block its function. Dr. Lidereau’s work may open new therapeutic strategies to prevent tumors from spreading, particularly in triple-negative breast cancers (TNBC), which are difficult to treat and more likely to metastasize.
What’s next: Her team will continue to validate their new therapeutic approach to prevent metastasis in TNBC and also identify genetic and molecular drivers of metastasis and drug resistance.
Metastatic breast cancer, also called Stage IV, is the most advanced form of breast cancer. While there are ways to slow its growth, there is no cure for it, so interventions are urgently needed to prevent metastasis. Dr. Lidereau is studying the molecular mechanisms underlying breast cancer progression and is testing a novel drug that can prevent tumors from spreading to other tissues.
Full Research Summary
Research area: Understanding and preventing the processes that drive tumor metastasis and resistance to therapies.
Impact: While there are ways to slow the growth of metastatic breast cancer (MBC), it is currently incurable. Dr. Lidereau is studying the early tumor processes that lead to metastasis of triple-negative breast cancers (TNBC). Her studies could inform the development of new therapeutic strategies for this often aggressive disease.
Current investigation: She and her team are testing a novel drug that blocks a protein, kindlin-1, which enhances the ability of cancer cells to become invasive.
What she’s learned so far: Dr. Lidereau has developed a molecule that blocks the function of kindlin-1, which inhibited cancer cell invasion in experimental models. She discovered a correlation between kindlin-1 expression and activation of the EGFR/RAS pathway, known to play a pivotal role in tumor progression via proliferation, survival, invasion, and immune evasion.
What’s next: Her team will continue to test their new therapeutic approach targeting kindlin-1 for prevention of metastasis in experimental models of TNBC. They also plan to further their genomic analyses of primary tumors and subsequent metastases to identify genes associated with breast cancer metastasis, the molecular processes driving organ-specific metastasis, and the potential drivers of resistance to treatments.
Dr. Rosette Lidereau received her PhD in oncology and immunology in 1987 from the Pasteur Institute (working with Chairman and Prof. Barret-Sinoussi) and completed a fellowship in the Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda (Prof. R. Callahan). In 1992, she was recruited by the INSERM (Institut National des Sciences et de la Recherche Médicale), where she served as a Research Director. From 2000, she headed the INSERM Unit U735, a laboratory dedicated to the molecular characterization of breast cancers at the Centre René Huguenin, Saint-Cloud, France.
Dr. Lidereau's scientific career has focused on the biology of breast cancer. Her research interests are the evaluation of oncogenes and the implication of tumor suppressor genes in breast tumorigenesis and their impact in the clinic as prognostic and predictive factors in breast cancer. Her work has been published in peer reviewed journals in which she has authored over 250 scientific articles. She has received several awards including the Henry et Mary-Jane Mitjavile prize from the Academy of Medicine (2005). In addition, she has been actively involved in numerous national and international organizations, including the international TRANSBIG research network and European Union Programmes (framework IV and VI).
Currently she pursues her research activities in the Genetics Laboratory in the Department of Tumor Biology at Institut Curie, Paris. Her investigations focus on the molecular determinants of breast cancer metastasis and their involvement in organ-specificity.